GO:2000584 negative regulation of platelet-derived growth factor receptor-alpha signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000584 describes any process that stops, prevents, or reduces the frequency, rate, or extent of platelet-derived growth factor receptor-alpha (PDGFR-alpha) signaling [1,5].
• The c-Cbl protein is a major negative regulator that promotes ubiquitination and degradation of PDGFR-alpha, thereby terminating its signaling [5,7].
• Dysregulation of this process contributes to cancers such as uterine cancer and gliomas, where PDGFR-alpha signaling is often aberrantly active.
• MicroRNA-146b-5p directly targets PDGFRA mRNA, adding a layer of post-transcriptional negative regulation important for erythropoiesis and megakaryocytopoiesis.
• Dynamic changes in PDGFR-alpha expression and its negative regulation are critical for alveolar fibroblast behavior during lung realveolarization.
• Studying GO:2000584 requires tools such as knockout, point-mutation, and knock-in cell models, along with CRISPR screening and bioinformatics to dissect regulatory networks [5,7,8].
Description
The Gene Ontology term GO:2000584, negative regulation of platelet-derived growth factor receptor-alpha signaling pathway, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of signaling through the platelet-derived growth factor receptor-alpha (PDGFR-alpha) [1,5]. PDGFR-alpha is a receptor tyrosine kinase that, upon binding to its ligands (PDGF-AA, -AB, -BB, -CC), undergoes autophosphorylation and initiates downstream cascades controlling cell proliferation, migration, and survival. Because excessive or prolonged PDGFR-alpha signaling drives pathological conditions such as fibrosis and cancer, cells have evolved multiple negative regulatory mechanisms to keep this pathway in check [3,5]. Understanding these mechanisms is essential for researchers aiming to manipulate PDGFR-alpha activity in disease models and for developing targeted therapies [3,8]. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:2000584, covering its definition, molecular players, disease relevance, and experimental approaches.
negative regulation of platelet-derived growth factor receptor-alpha signaling pathway At A Glance
| GO ID | GO:2000584 |
|---|---|
| GO term | negative regulation of platelet-derived growth factor receptor-alpha signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of alphaPDGF receptor signaling pathway; negative regulation of PDGFR-alpha signaling pathway; negative regulation of PDGF receptor-alpha signaling pathway; negative regulation of platelet-derived growth factor receptor-alpha signalling pathway |
| Major function | Attenuation or termination of PDGFR-alpha-mediated signal transduction to prevent excessive cell proliferation, migration, and survival [5,7]. |
| Key regulator | c-Cbl (CBL), an E3 ubiquitin ligase that promotes PDGFR-alpha ubiquitination and degradation [5,7]. |
| Additional regulator | MicroRNA-146b-5p, which targets PDGFRA mRNA for post-transcriptional repression. |
| Physiological context | Important for lung alveolarization, erythropoiesis, and megakaryocytopoiesis [2,8]. |
| Disease relevance | Dysregulation linked to cancers (e.g., uterine cancer, gliomas) and fibrotic disorders. |
What Is GO:2000584?
According to the Gene Ontology, GO:2000584 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of platelet-derived growth factor receptor-alpha signaling pathway. In other words, it encompasses all cellular mechanisms that attenuate or shut down signal transduction initiated by PDGFR-alpha, including receptor ubiquitination, degradation, dephosphorylation, and inhibition of downstream effectors [5,7].
Why Is negative regulation of platelet-derived growth factor receptor-alpha signaling pathway Important in Cell Biology?
GO:2000584 is critically important because PDGFR-alpha signaling is a potent driver of cell proliferation and migration, and its negative regulation ensures that these processes are tightly controlled. Loss of negative regulation can lead to uncontrolled PDGFR-alpha activity, which is implicated in various malignancies and fibrotic diseases. For example, in uterine cancer, PDGFR-alpha blockade reduces tumor growth, highlighting the therapeutic potential of targeting this pathway. Moreover, negative regulation of PDGFR-alpha is essential for normal physiological processes such as lung alveolarization and hematopoiesis [2,8]. Therefore, understanding the molecular mechanisms of GO:2000584 provides insights into disease pathogenesis and identifies targets for therapeutic intervention.
• Prevents excessive cell proliferation and migration driven by PDGFR-alpha.
• Its dysregulation is associated with cancers such as uterine cancer and gliomas.
• Plays a role in lung alveolarization and repair.
• Regulates erythropoiesis and megakaryocytopoiesis via microRNA-146b-5p.
• c-Cbl-mediated negative regulation is a paradigm for receptor tyrosine kinase downregulation [5,7].
• Provides potential therapeutic targets for cancer and fibrotic diseases.
• Helps maintain tissue homeostasis by balancing growth factor signaling.
• Informs the design of CRISPR-based models to study PDGFR-alpha-related disorders [5,7,8].
What Happens During negative regulation of platelet-derived growth factor receptor-alpha signaling pathway?
Receptor Ubiquitination and Degradation
In simple terms: The cell tags the PDGFR-alpha receptor with ubiquitin molecules, marking it for destruction.
A key mechanism of negative regulation involves the E3 ubiquitin ligase c-Cbl, which binds to phosphorylated PDGFR-alpha and mediates its ubiquitination [5,7]. This ubiquitination targets the receptor for proteasomal or lysosomal degradation, effectively reducing the number of receptors available for signaling. The tyrosine kinase-binding domain of Cbl is critical for this process, as mutations in this domain abolish its ability to negatively regulate PDGFR-dependent cell proliferation.
Post-transcriptional Regulation by MicroRNAs
In simple terms: Small RNA molecules can block the production of the PDGFR-alpha protein by binding to its mRNA.
MicroRNA-146b-5p directly targets the 3' untranslated region of PDGFRA mRNA, leading to reduced PDGFR-alpha protein levels. This microRNA-mediated repression negatively regulates PDGFR-alpha signaling and is important for normal erythropoiesis and megakaryocytopoiesis. Thus, microRNAs provide an additional layer of negative regulation at the post-transcriptional level.
Inhibition of Downstream Signaling
In simple terms: Even if the receptor is active, the cell can block the signals it sends to the nucleus.
Negative regulation can also occur downstream of the receptor. For instance, Cbl proteins can compete with positive effectors for binding to PDGFR-alpha, thereby attenuating downstream pathways such as PI3K/AKT and MAPK. Additionally, phosphatases may dephosphorylate key tyrosine residues on PDGFR-alpha, preventing the recruitment of signaling molecules. These mechanisms collectively ensure that PDGFR-alpha signaling is transient and controlled.
Regulation of Receptor Expression Levels
In simple terms: The cell can simply make fewer receptors to reduce signaling.
Dynamic regulation of PDGFR-alpha expression itself can serve as a negative regulatory mechanism. For example, in alveolar fibroblasts during realveolarization, PDGFR-alpha expression is dynamically regulated, and its downregulation may limit signaling. This level of control ensures that PDGFR-alpha activity is matched to physiological needs.
Key Genes Involved in GO:2000584 negative regulation of platelet-derived growth factor receptor-alpha signaling pathway
The following genes and proteins are central to the negative regulation of PDGFR-alpha signaling, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CBL | E3 ubiquitin ligase that ubiquitinates PDGFR-alpha, leading to its degradation [5,7]. | Key negative regulator; mutations linked to oncogenesis [1,6]. |
| PDGFRA | Encodes the platelet-derived growth factor receptor-alpha, the target of negative regulation. | Mutations and overexpression associated with cancers and developmental disorders. |
| MIR146B | MicroRNA-146b-5p targets PDGFRA mRNA for repression. | Regulates erythropoiesis and megakaryocytopoiesis. |
| GNA12 | GTPase-deficient mutant transactivates PDGFR-alpha, providing a model for studying negative regulation. | Used to dissect pathways that counteract PDGFR-alpha activation. |
| CBLB | Related Cbl family member with potential redundant roles in negative regulation. | May compensate for CBL loss in some contexts. |
| CBLC | Another Cbl family member, less studied in PDGFR-alpha regulation. | Potential target for CRISPR screening. |
| PTPN11 | Protein tyrosine phosphatase that may dephosphorylate PDGFR-alpha. | Candidate negative regulator; mutations in cancers. |
| INPP5D | Phosphatidylinositol phosphatase that can attenuate PI3K signaling downstream of PDGFR-alpha. | Potential modulator of PDGFR-alpha signaling. |
| SOCS1 | Suppressor of cytokine signaling, may indirectly affect PDGFR-alpha signaling. | Possible crosstalk with negative regulation. |
| SOCS3 | Another SOCS family member, potential negative regulator. | May influence PDGFR-alpha signaling in inflammation. |
| GRB2 | Adaptor protein that can compete with Cbl for binding to PDGFR-alpha. | Balance between GRB2 and Cbl determines signaling outcome. |
| PIK3R1 | Regulatory subunit of PI3K, downstream effector that can be negatively regulated. | Target for modulating PDGFR-alpha-driven proliferation. |
| AKT1 | Serine/threonine kinase downstream of PDGFR-alpha; its negative regulation contributes to pathway shutdown. | Readout for PDGFR-alpha activity. |
| MAPK1 | ERK2, downstream effector; negative regulation of this kinase attenuates PDGFR-alpha signaling. | Commonly assessed by western blot. |
| MAPK3 | ERK1, similar to MAPK1. | Readout for pathway activity. |
| STAT3 | Transcription factor activated by PDGFR-alpha; its negative regulation may involve SOCS proteins. | Potential feedback regulator. |
| JAK2 | Kinase that can be activated by PDGFR-alpha; negative regulation may involve phosphatases. | Target for inhibitors. |
| SRC | Non-receptor tyrosine kinase that can be activated by PDGFR-alpha; negative regulation may involve Csk. | Modulates PDGFR-alpha signaling. |
How Is negative regulation of platelet-derived growth factor receptor-alpha signaling pathway Regulated?
The negative regulation of PDGFR-alpha signaling is itself subject to regulation. For example, the expression of Cbl can be induced by cytokines, creating a feedback loop that limits PDGFR-alpha activity. Additionally, microRNA-146b-5p levels are dynamically regulated during erythropoiesis, allowing for stage-specific repression of PDGFRA. Phosphatases such as SHP-2 (PTPN11) can be recruited to activated PDGFR-alpha and dephosphorylate key residues, thereby terminating signaling. The balance between positive and negative regulators determines the intensity and duration of PDGFR-alpha signaling, and disruption of this balance can lead to disease [3,6].
negative regulation of platelet-derived growth factor receptor-alpha signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CBL | Myeloid malignancies, oncogenesis [1,6] | Knockout or point-mutation cell lines (e.g., K562) |
| PDGFRA | Uterine cancer, gliomas | Overexpression or knock-in of mutant PDGFRA in cancer cell lines |
| MIR146B | Erythropoiesis and megakaryocytopoiesis disorders | Knockout of miR-146b in hematopoietic stem cells |
| GNA12 | Cancer, cell transformation | Overexpression of GTPase-deficient Gα12 mutant |
| PTPN11 | Noonan syndrome, leukemias | Point mutation knock-in (e.g., D61G) in mice |
Cancer
Dysregulation of PDGFR-alpha signaling is implicated in various cancers. In uterine cancer, PDGFR-alpha blockade reduces cell proliferation and tumor growth, suggesting that loss of negative regulation contributes to oncogenesis. Mutations in CBL that impair its negative regulatory function have been found in myeloid malignancies, leading to enhanced PDGFR-alpha signaling [1,6]. Therefore, restoring negative regulation is a potential therapeutic strategy.
Fibrotic Disorders
PDGFR-alpha signaling promotes fibroblast proliferation and extracellular matrix deposition, processes central to fibrosis. Negative regulation of this pathway is essential to prevent excessive fibrosis. In lung alveolarization, dynamic regulation of PDGFR-alpha expression is required for proper alveolar development, and its dysregulation may contribute to bronchopulmonary dysplasia.
Hematological Disorders
MicroRNA-146b-5p-mediated negative regulation of PDGFRA is important for normal erythropoiesis and megakaryocytopoiesis. Disruption of this regulation could lead to hematological abnormalities, although direct evidence in human disease is still emerging.
From negative regulation of platelet-derived growth factor receptor-alpha signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CBL enhance PDGFR-alpha signaling? | CBL knockout cell lines (e.g., using CRISPR-Cas9) |
| Does a specific point mutation in CBL abolish its negative regulatory function? | Point-mutation knock-in of CBL tyrosine kinase-binding domain mutant |
| Does miR-146b-5p directly target PDGFRA? | Knock-in of miR-146b-5p binding site mutation in PDGFRA 3'UTR |
| Can tagged PDGFR-alpha be used to track its degradation? | Knock-in of HA- or GFP-tagged PDGFRA |
| Does overexpression of Cbl reduce PDGFR-alpha levels? | Overexpression of CBL in PDGFR-alpha-expressing cells |
| What genes modulate PDGFR-alpha signaling? | Genome-wide CRISPR knockout library screening [5,7] |
How to Study the negative regulation of platelet-derived growth factor receptor-alpha signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR-Cas9 knockout | Loss of gene function | Study negative regulators like CBL |
| RNA-seq | Transcriptome changes | Assess miR-146b-5p effects on PDGFRA mRNA |
| Proteomics | Protein interactions and modifications | Identify ubiquitination sites on PDGFR-alpha |
| Western blot | Protein levels and phosphorylation | Measure PDGFR-alpha degradation and downstream signaling |
| Immunoprecipitation | Protein-protein interactions | Detect Cbl-PDGFR-alpha binding |
| Luciferase reporter assay | 3'UTR regulation | Validate miR-146b-5p targeting of PDGFRA |
| Live-cell imaging | Receptor trafficking | Track PDGFR-alpha internalization |
| CRISPR library screening | Genome-wide gene function | Identify novel negative regulators [5,7] |
CRISPR-Cas9 Knockout
CRISPR-Cas9 knockout of negative regulators such as CBL can be used to assess their role in PDGFR-alpha signaling. For example, knocking out CBL in cell lines leads to increased PDGFR-alpha levels and enhanced downstream signaling. This approach is powerful for identifying essential components of the negative regulation pathway.
RNA Sequencing (RNA-seq)
RNA-seq can measure changes in gene expression upon manipulation of negative regulators. For instance, overexpression of miR-146b-5p reduces PDGFRA mRNA levels, which can be quantified by RNA-seq. This method provides a global view of transcriptional changes.
Proteomics and Ubiquitination Assays
Mass spectrometry-based proteomics can identify ubiquitination sites on PDGFR-alpha mediated by Cbl. Immunoprecipitation followed by western blotting for ubiquitin can confirm receptor ubiquitination. These methods directly measure the post-translational modifications that drive negative regulation.
Imaging and Live-Cell Tracking
Fluorescence microscopy of tagged PDGFR-alpha can visualize receptor internalization and degradation in real time. This approach helps to dissect the spatiotemporal dynamics of negative regulation.
How CRISPR Can Be Used to Study GO:2000584 negative regulation of platelet-derived growth factor receptor-alpha signaling pathway
Knockout
CRISPR-Cas9 knockout is used to create cell models lacking specific negative regulators, such as CBL, to study their role in PDGFR-alpha signaling. These models help determine whether a gene is necessary for negative regulation.
Point Mutation
Point mutations can be introduced into genes like CBL to mimic clinical mutations that impair negative regulation. For example, mutation of the tyrosine kinase-binding domain of Cbl abolishes its ability to downregulate PDGFR-alpha. Such models are valuable for understanding disease mechanisms.
Knock-in
Knock-in of tagged PDGFR-alpha (e.g., HA or GFP) allows for tracking receptor degradation and trafficking. Additionally, knock-in of mutated microRNA binding sites in the PDGFRA 3'UTR can validate microRNA-mediated regulation.
Overexpression
Overexpression of negative regulators like Cbl or miR-146b-5p can suppress PDGFR-alpha signaling and reduce cell proliferation [7,8]. This approach is useful for confirming the sufficiency of a regulator to inhibit the pathway.
How EDITGENE Supports negative regulation of platelet-derived growth factor receptor-alpha signaling pathway Research
Researchers studying negative regulation of platelet-derived growth factor receptor-alpha signaling pathway-related genes often need to determine whether a candidate gene is causally involved in attenuating PDGFR-alpha signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models, enabling functional validation of genes like CBL, PDGFRA, and MIR146B.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of platelet-derived growth factor receptor-alpha signaling pathway research.
Frequently Asked Questions About negative regulation of platelet-derived growth factor receptor-alpha signaling pathway
What is GO:2000584?
GO:2000584 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of platelet-derived growth factor receptor-alpha signaling pathway [1,5].
What genes are involved in negative regulation of PDGFR-alpha signaling?
Key genes include CBL, which ubiquitinates PDGFR-alpha for degradation, and MIR146B, which targets PDGFRA mRNA [5,7,8].
How does Cbl negatively regulate PDGFR-alpha?
Cbl binds to phosphorylated PDGFR-alpha and mediates its ubiquitination, leading to receptor degradation and reduced signaling [5,7].
What diseases are associated with dysregulation of this pathway?
Dysregulation is linked to cancers such as uterine cancer and gliomas, as well as fibrotic disorders.
What is the role of microRNA-146b-5p in PDGFR-alpha regulation?
MicroRNA-146b-5p directly targets PDGFRA mRNA, reducing receptor levels and negatively regulating signaling in erythropoiesis and megakaryocytopoiesis.
How can I study negative regulation of PDGFR-alpha signaling?
CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics, and imaging are common approaches [5,7,8].
What cell models are available for studying GO:2000584?
Knockout cell lines for CBL, point-mutation models for CBL, tagged PDGFRA knock-in, and overexpression models for Cbl or miR-146b-5p [5,7,8].
Does PDGFR-alpha signaling play a role in lung development?
Yes, dynamic regulation of PDGFR-alpha expression in alveolar fibroblasts is important for realveolarization.
What is the clinical significance of PDGFR-alpha blockade?
PDGFR-alpha blockade reduces tumor growth in uterine cancer, suggesting therapeutic potential.
How does EDITGENE support research on this pathway?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study negative regulation of PDGFR-alpha signaling [5,7,8].
Conclusion
GO:2000584, negative regulation of platelet-derived growth factor receptor-alpha signaling pathway, is a critical biological process that ensures proper control of PDGFR-alpha activity. Key mechanisms include Cbl-mediated ubiquitination and degradation of the receptor, as well as microRNA-146b-5p-mediated post-transcriptional repression [5,7,8]. Dysregulation of this process contributes to cancer and fibrotic diseases, making it an attractive target for therapeutic intervention. Researchers can leverage CRISPR-based models and multi-omics approaches to dissect the molecular players and develop novel treatments. EDITGENE provides comprehensive services to support such studies, from knockout and knock-in cell models to library screening and bioinformatics.
References
- 1. Lupher ML Jr et al.. 1998. The c-Cbl oncoprotein.. Int J Biochem Cell Biol 30(4):439-44 PMID: 9675877
- 2. Chen L et al.. 2012. Dynamic regulation of platelet-derived growth factor receptor α expression in alveolar fibroblasts during realveolarization.. Am J Respir Cell Mol Biol 47(4):517-27 PMID: 22652199
- 3. Roh JW et al.. 2014. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.. Clin Cancer Res 20(10):2740-50 PMID: 24634380
- 4. Kumar RN et al.. 2006. Transactivation of platelet-derived growth factor receptor alpha by the GTPase-deficient activated mutant of Galpha12.. Mol Cell Biol 26(1):50-62 PMID: 16354679
- 5. Miyake S et al.. 1999. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain.. J Biol Chem 274(23):16619-28 PMID: 10347229
- 6. Bonita DP et al.. 1997. Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity.. Mol Cell Biol 17(8):4597-610 PMID: 9234717
- 7. Miyake S et al.. 1998. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha.. Proc Natl Acad Sci U S A 95(14):7927-32 PMID: 9653117
- 8. Zhai PF et al.. 2014. The regulatory roles of microRNA-146b-5p and its target platelet-derived growth factor receptor α (PDGFRA) in erythropoiesis and megakaryocytopoiesis.. J Biol Chem 289(33):22600-22613 PMID: 24982425
